Compare SSTK & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSTK | OCGN |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | United States | United States |
| Employees | N/A | 116 |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 570.9M | 474.8M |
| IPO Year | 2012 | 2014 |
| Metric | SSTK | OCGN |
|---|---|---|
| Price | $5.80 | $1.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $25.00 | $9.75 |
| AVG Volume (30 Days) | 1.3M | ★ 4.4M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 8.61% | N/A |
| EPS Growth | ★ 23.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.35 | N/A |
| Revenue Next Year | N/A | $1,718.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.17 | $0.98 |
| 52 Week High | $29.50 | $2.73 |
| Indicator | SSTK | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 34.12 | 52.17 |
| Support Level | $5.17 | $1.30 |
| Resistance Level | $6.65 | $1.58 |
| Average True Range (ATR) | 0.50 | 0.07 |
| MACD | 0.23 | 0.02 |
| Stochastic Oscillator | 41.13 | 66.67 |
Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").